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Abstract
We evaluated the in vitro effect on clonogenic potential (CFU-GM) and apoptosis in myelodysplastic syndromes (MDS)
progenitors of an anti-oxidant (N-acetylcysteine, NAC) and:or a differentiating (all-trans retinoic acid, ATRA) agent. NAC
significantly reduced apoptosis, both NAC and ATRA induced an increase in CFU-GM, but NAC seemed to be particularly
effective in the high risk (HR) MDS. NACATRA conferred a significant advantage in terms of CFU-GM with respect to NAC
and ATRA alone. Tumor Necrosis Factor-a (TNF-a) levels decreased after incubation with NAC in the MDS samples. This study
shows that ineffective hemopoiesis in MDS could benefit from both NAC and ATRA, suggesting that anti-oxidant treatment may
play a role in guaranteeing MDS cell survival, predisposing them towards differentiation. © 2000 Published by Elsevier Science
Ltd. All rights reserved.
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1. Introduction
Increased bone marrow apoptosis and ineffective
hemopoiesis are the two main characteristics of the
myelodysplastic syndromes (MDS) [1–6]. The former,
which is at least partially responsible for premature
intramedullary cell death, is particularly pronounced in
low-risk MDS (such as refractory anemia, RA and
refractory anemia with ring sideroblasts, RARS),
whereas the latter leads to the well known maturation
arrest of bone marrow (BM) progenitors, but both
determine the often severe and life-threatening cytope-
nia(s) typical of MDS.
It is well documented that MDS patients have in-
creased serum Tumor Necrosis Factor-a (TNF-a) levels
[7–11], which may be responsible for pro-apoptotic
oxidative damage by inducing the generation of free
radicals [12–16]. In line with this hypothesis, Peddie et
al. [17] have demonstrated the presence of oxidative
damage and a reduction in intracellular glutathione
(GSH) in MDS CD34 cells, and a number of in vitro
studies have shown the ability of the antioxidant thiol
N-acetylcysteine (NAC) to reduce the apoptosis in-
duced by free radicals in neuronal and leukemic cell
lines by increasing the supply of intracellular GSH
[18–20]. NAC also acts as an antiapoptotic agent by
inhibiting TNF-a release from lymphocytes and acces-
sory cells [21].
MDS bone marrow (BM) progenitors can be induced
to differentiate and mature in vitro by using various
differentiating agents, such as vitamin D3 and E, Ara-
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C, butyrates and amifostine and this has provided the
rationale for several clinical trials [22].
ATRA is a natural metabolite of retinol, whose
differentiating activity has also been demonstrated in
non-APL blast cells [23]. However, when used in vivo,
the ability of ATRA alone to restore defective hemo-
poiesis in MDS has not always been demonstrated
[24–30].
On the basis of these observations we incubated
MDS progenitor cells in vitro first with NAC alone and
after 24 h with ATRA alone or in combination in order
to explore their activity in terms of enhanced clono-
genic potential (CFU-GM), reduced apoptosis and
stimulated differentiation. The rationale of the sequence
(first NAC then ATRA) was based on the hypothesis of
first reducing the degree of apoptosis by means of an
antioxidant, and then stimulating differentiation via
ATRA. The possible role of TNF-a in inducing free
radicals was evaluated by determining TNF-a levels in
bone marrow plasma and in supernatants of liquid
cultures.
2. Patients
The BM cells were obtained from 25 patients with de
novo MDS (21 males and 4 females, with a median age
of 68 years: range 34–86) and seven normal bone
marrow donors, after they had given their informed
consent. On the basis of the FAB criteria, the patients
were classified as being affected by RA (n6), RARS
(n7), RAEB (n10) and RAEB-t (n2). For the
purpose of the study, we classified RARARS as low
risk (LR) MDS and RAEBRAEB-t as high risk
(HR) MDS.
3. Methods
3.1. Cell preparation
The BM samples were collected in preservative-free
heparin. The mononuclear cells (MNCs) were separated
by means of gradient centrifugation using Ficoll
Lymphoprep (Nicomed Pharma Oslo, Norway), evalu-
ated for apoptosis and then suspended in IMDM
(Gibco Europe, Paisley, UK) with 10% FCS (Hyclone,
Logan, Utah, USA ) at a concentration of 1106:ml
and incubated at 37°C in 5% CO29NAC 0.5 mM for
24 h. After this time, some of the cells9NAC (Sigma,
Saint Louis, MO, USA) were evaluated for CFU-GM
and apoptosis and others were cultured9ATRA 5 mM
(kindly provided by Roche) for a further 24 h. After a
total culture time of 48 h, the cells incubated with
ATRA, NAC, NACATRA as well as the control
cells were again tested for CFU-GM and apoptosis.
Due to the scanty cell recovery from MDS BM, the
samples incubated for 48 h with NAC alone were
evaluated in only 12:25 cases. The viability after liquid
incubation was always \90% evaluated by the Trypan
blue exclusion test.
3.2. Apoptosis
Apoptosis was evaluated by means of a TdT:dUTP
assay using the commercially available ‘In Situ Cell
Death Fluorescein Detection Kit’ (Boehringer
Mannheim, Germany). Briefly, 1–2106 cells were
fixed in cold ethanol 70% in PBS, and stored at 4°C
until use. Before staining, the cells were washed in PBS,
permeabilized with 100 ml TritonX-100 0.1% in sodium
citrate 0.1% for 2 min on ice, and again washed twice in
PBS. After incubation for 1 h at 37°C with dUTP
FITC, with and without TdT, samples were again
washed in PBS, resuspended in 500 ml of PBS and made
ready for cytofluorimetric analysis. A total of 1104
events were analyzed.
3.3. CFU-GM
A volume of 1105 cells:ml in IMDM were cultured
in 1 ml of a mixture containing 20% FCS, 0.3% agar,
GM-CSF 200 U:ml, IL-3 100 U:ml and SCF 8 U:ml
(Genzyme Cambridge, MA, USA) and the plates were
incubated in humidified air with 5% CO2 at 37°C for 14
days. The aggregates containing \50 cells were scored
as colonies, whereas those containing B50 cells were
scored as clusters. All of the cultures were set up in
quadruplicate. In order to exclude interference due to
the absence of reducing equivalents in the agar assay,
clonogenic tests using methylcellulose (HF 4434, Stem
Cell Technologies Vancouver, Canada) were also made
in a subset of patients.
3.4. TNF-a le6els in BM plasma and liquid culture
The plasma samples obtained by spinning the BM
samples at 3000 rpm were stored at 20°C until used,
and then investigated for their TNF-a content by
means of a commercially available immunoenzymatic-
assay kit (Medgenix Diagnostic, Fleurus, Belgium). The
TNF-a levels in the supernatants of 24 h liquid cultures
were also evaluated. The minimum detectable dose of
TNF-a was 3.0 pg:ml.
3.5. Statistical analysis
The Wilcoxon matched pairs signed ranks test was
used to evaluate within-group differences, and the
Mann–Whitney test for differences between groups. A
P value of B0.05 was considered to be statistically
significant.
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4. Results
4.1. E6aluation of apoptosis in fresh bone marrow
mononuclear cells (BMMNCs)
The apoptosis evaluated in fresh MDS BMMNCs
was higher than that observed in the normal samples
(1.6790.16 SE versus 1.4990.27, n.s.). Apoptosis was
even higher in the LR group (LR: 2.0290.22, PB0.05
versus normals).
4.2. E6aluation of apoptosis after 24 h of incubation
with NAC
In the normal samples, apoptosis was significantly
(PB0.05) less after NAC incubation in comparison
with controls (3.0390.74 versus 4.190.84). It was also
less after NAC stimulation in the MDS samples as a
whole (2.1290.52 versus 3.4490.66) (PB0.01), as
well as in the two subgroups (LR: 2.0690.68 versus
3.6790.93; HR: 2.1890.83 versus 3.1690.96) (PB
0.05 and PB0.01, respectively) (Fig. 1).
4.3. Clonogenic assay (CFU-GM) after 24 h of
incubation with NAC
The number of CFU-GM was significantly higher in
the NAC treated normal than in the controls (195.69
49.72 versus 153.8945.98) (PB0.05). A significant
increase in the number of CFU-GM was also observed
in the MDS patients after NAC incubation (MDS:
73.39912.88 versus 57.3911.24, PB0.01; LR:
78.69914.59 versus 61.85913.79, PB0.01; HR:
66.5923.54 versus 51.4919.34, PB0.05) (Fig. 2).
4.4. E6aluation of apoptosis after 48 h of incubation
with NAC9ATRA
ATRA alone did not modify the percentage of apop-
tosis in either the normals or MDS samples, but incu-
bation with NACATRA led to a significant decrease
in the apoptotic rate in both the normal (2.3690.61
versus 3.7490.97, PB0.05) and MDS samples (2.069
0.44 versus 3.7890.7, PB0.01). The same was ob-
served in both the LR (PB0.05) and HR (P0.06)
subgroups (LR: 1.6290.34 versus 3.390.69; HR:
2.7190.96 versus 4.3691.23) (Fig. 3). Apoptosis was
also less in the 12 MDS samples evaluated after 48 h
NAC stimulation than in controls (1.5290.85 versus
3.1691.08, PB0.05) (Fig. 3a).
4.5. Clonogenic assay (CFU-GM) after 48 h of
incubation with NAC9ATRA
Both ATRA and NACATRA significantly in-
creased clonogenic activity in both the normal (PB
0.05) and MDS samples (PB0.01) (normal: CTRL
172.2936.06, ATRA 329.8962.56, NACATRA
361965.29; MDS: CTRL 59.67915.28, ATRA
74.76914.95, NACATRA 87.59919.56).
However although incubation with ATRA alone in-
creased clonogenic activity in both MDS subgroups,
this was statistically significant only in the LR patients
(PB0.01); the increase after incubation with NAC
ATRA was statistically significant in both the LR
(PB0.01) and HR patients (PB0.05) (mean values
LR: CTRL 78.58921.83, ATRA 100.67921.64,
NACATRA 110.08929.06; HR: CTRL 34.449
18.7, ATRA 40.22913.59, NACATRA 55.119
Fig. 1. Effect of NAC on apoptosis after 24 h of liquid culture. * PB0.05, ** PB0.01 versus controls.
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Fig. 2. Effect of NAC on clonogenic activity (CFU-GM) after 24 h of liquid culture. * PB0.05, ** PB0.01 versus controls.
20.09) (Fig. 4). The NACATRA combination con-
ferred a significant (PB0.05) advantage in terms of
clonogenic potentials with respect to ATRA in the
MDS samples as a whole.
After 48 h incubation with NAC alone, the increase
in the clonogenic activity of the MDS samples was
statistically significant (61.5912.63 versus 42.759
10.48, PB0.05) in comparison with the control sam-
ples, but significantly (PB0.05) less than that observed
after incubation with NACATRA (69913.61) (Fig.
4a).
Analysis of the colony:cluster ratio after 24 and 48 h
always revealed a moderate and non-significant increase
in the MDS samples as a whole (24 h: CTRL 29.429
11.48, NAC 35.99912.92; 48 h: CTRL 24.8698.38,
ATRA 37.35912.89, NAC 32.83916.33, NAC
ATRA 37.27910.91) as well as in the LR (24 h: CTRL
45.93920.41, NAC 56.06920.46; 48 h: CTRL
37.13913.84, ATRA 54.98921.04, NAC 52.039
29.12, NAC ATRA 49.49916.17) and HR patients
(24 h: CTRL 11.0894.98, NAC 13.6996.66; 48 h:
CTRL 11.0596.55, ATRA 17.52911.46, NAC
13.6398.81, NACATRA 22913.02). We never ob-
served a reduction in the colony:cluster ratio of any
patient sample or under any culture conditions.
The data obtained using methylcellulose assay were
comparable to those derived from agar assay (data not
shown).
4.6. TNF-a le6els in BM plasma and liquid culture
BM plasma TNF-a levels were significantly higher
(PB0.01) in the MDS patients (36.9493.58, range
15.53–70.81 pg:ml) than in the normal subjects (8.389
0.44, range 3.06–13.77 pg:ml). No difference was found
between the LR and HR subgroups, although the
highest TNF-a (70.81 pg:ml) value was observed in a
LR patient (Fig. 5). However, the patients with TNF-a
levels of \50 pg:ml also responded to NAC in terms
of CFU-GM and apoptosis.
The TNF-a levels in the supernatants of 24 h BM
MDS liquid cultures showed a significant (PB0.05)
decrease after incubation with NAC (16.9996.22) in
comparison with the control samples (26.7295.78)
(Fig. 6).
5. Discussion
The apparently bizarre behaviour of MDS hemato-
poiesis, which is expressed in the form of peripheral
cytopenia associated with normo-hypercellular bone
marrow, is the consequence of increased apoptosis and
the maturation arrest of MDS hemopoietic progenitors.
It is also known that high levels of TNF-a (a pro-apop-
totic agent) are found in the serum of MDS patients,
and so the documented oxidative damage to MDS
CD34 cells could also be the result of TNF-a in-
duced free radical production.
On the basis of these observations, we evaluated the
effect of an antioxidant (and anti-apoptotic) agent
(NAC) and a differentiating agent (ATRA), alone and
in association, on clonogenic activity and apoptosis in
MDS BM mononuclear cells.
Our study showed the in vitro ability of NAC to
enhance hemopoiesis in MDS, even in the presence of a
large percentage of blasts. After 24 and 48 h of incuba-
tion with NAC, we observed an increase in the number
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of CFU-GM in the MDS samples as a whole, as well as
in the LR and HR groups. A consensual decrease in the
apoptotic rate was seen after 24 and 48 h NAC stimula-
tion. These data indirectly suggest that apoptosis plays
a role even in the MDS HR subset. Moreover, ATRA
did not have any adverse effects on erythroid colonies,
evaluated in methylcellulose assay (data not shown).
NAC alone, in fact, slightly enhanced the number of
BFU-E colonies whereas the association ATRA-
NAC neither increased nor decreased the number of
colonies.
As a result of the physiological senescence of cul-
tured cells, the apoptosis evaluated in the control sam-
ples (i.e. after incubation with medium alone) was
higher than that observed in the fresh samples. More-
over, the level of apoptosis was particularly high in the
MDS HR subgroup. Since our observations are derived
from a mixed population of all BMMNCs, we cannot
be sure whether or not this phenomenon is due to
CD34 cells. However this singular behaviour may be
explained by the poor self-renewal of MDS blasts,
which are less capable of proliferation than leukemic
blasts, as has previously been pointed out by Aul et al.
[31]. A propensity towards apoptosis therefore seems to
coexist with enhanced proliferation in HR MDS cells,
and this may be responsible for the relative indolence of
RAEB and RAEB-t.
The efficacy of NAC may be due to an increase in
intracellular glutathione (GSH) levels in MDS CD34
cells, which in turn provides protection against the
apoptosis induced by free radicals. Furthermore, NAC
may also prevent the release of TNF-a from the
lymphocytes still present in BM liquid cultures, a hy-
pothesis that is apparently supported by the decreased
Fig. 3. Effect of NAC and:or ATRA on apoptosis after 48 h of liquid culture. * PB0.05, ** PB0.01, ° P0.06 versus controls.
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Fig. 4. Effect of NAC and:or ATRA on clonogenic activity (CFU-GM) after 48 h of liquid culture. * PB0.05, ** PB0.01 versus controls.
release of TNF-a in the supernatant of the liquid
cultures. NAC was also effective in the patients with
the highest TNF-a levels.
On the contrary, and as expected, ATRA did not
modify the apoptotic rate of MDS or normal BM cells,
and a significantly enhanced clonogenic activity was
only observed in the MDS samples as a whole and in
the LR sub-group, thus suggesting that only patients
with a low degree of BM blasts retain differentiative
ability. The fact that, in all of the MDS samples, the
NACATRA combination seemed to confer an ad-
vantage over the use of either substances alone in terms
of clonogenic activity suggests that anti-oxidant treat-
ment may play a key role in guaranteeing MDS cell
survival and predisposing them towards differentiation.
There was no evidence that NAC or ATRA add any
leukemogenic effect on MDS BM cells, as the number
of clusters remained the same after stimulation with
either substance, whereas the number of colonies al-
ways increased.
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Fig. 5. Bone marrow plasma TNF-a levels. * PB0.05, ** PB0.01 versus controls.
It has recently been reported that combined therapy
with ciprofloxacin, pentoxifylline and dexamethasone is
efficacious in reducing TNF-a levels and improving
hemopoiesis in MDS patients [9]. Moreover, List et al.
[32] have demonstrated that the aminothiol amyfostine
is capable of improving the in vitro clonogenic activity
of MDS hemopoietic precursors. The in vivo results seem
to be encouraging [33], although Bowen et al. [34]
observed a poor response rate to amyfostine therapy. Our
own in vitro results strongly suggest that a substance with
a very low toxicity profile such as NAC could be included
in the non-cytotoxic therapy of MDS.
Fig. 6. TNF-a levels after 24 h cultures. * PB0.05 versus controls.
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